Health Affairs, 24, no. 4 (2005): 928-937 doi: 10.1377/hlthaff.24.4.928 © 2005 by Project HOPE	New Online   Obama's Success & Next Steps   3 Health Policy Options for President Obama   A Hybrid Proposal   Bipartisan Compromise

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Malenka, D. J. Articles by Wennberg, J. E. Search for Related Content PubMed PubMed Citation Articles by Malenka, D. J. Articles by Wennberg, J. E. Related Collections Health Reform Legal/Regulatory Issues Medicare Business Of Health Pharmaceuticals Research And Technology Consumer Issues

FDA Under Scrutiny

Postmarketing Surveillance Of Medical Devices Using Medicare Claims

The current system of postmarketing surveillance of high-risk medical devices could be improved by taking advantage of the administrative billing data collected by the Centers for Medicare and Medicaid Services (CMS) to systematically monitor for adverse events that may signal device-related problems. In this paper we use the current concern about the excess risk associated with drug-eluting coronary stents to highlight the strengths and weaknesses of claims data for postmarketing surveillance and propose a pilot collaboration between government, industry, and academe to systematically explore the use of Medicare claims data for this purpose.

                      What's this?